These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38518779)

  • 1. Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance.
    Ogega CO; Skinner NE; Schoenle MV; Wilcox XE; Frumento N; Wright DA; Paul HT; Sinnis-Bourozikas A; Clark KE; Figueroa A; Bjorkman PJ; Ray SC; Flyak AI; Bailey JR
    Immunity; 2024 Apr; 57(4):890-903.e6. PubMed ID: 38518779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
    Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection.
    Frumento N; Sinnis-Bourozikas A; Paul HT; Stavrakis G; Zahid MN; Wang S; Ray SC; Flyak AI; Shaw GM; Cox AL; Bailey JR
    Immunity; 2024 Jan; 57(1):40-51.e5. PubMed ID: 38171362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convergent antibody responses are associated with broad neutralization of hepatitis C virus.
    Skinner NE; Ogega CO; Frumento N; Clark KE; Yegnasubramanian S; Schuebel K; Meyers J; Gupta A; Wheelan S; Cox AL; Crowe JE; Ray SC; Bailey JR
    Front Immunol; 2023; 14():1135841. PubMed ID: 37033983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins.
    Chen F; Tzarum N; Lin X; Giang E; Velázquez-Moctezuma R; Augestad EH; Nagy K; He L; Hernandez M; Fouch ME; Grinyó A; Chavez D; Doranz BJ; Prentoe J; Stanfield RL; Lanford R; Bukh J; Wilson IA; Zhu J; Law M
    Immunity; 2021 Apr; 54(4):781-796.e4. PubMed ID: 33675683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
    McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE
    J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection.
    Kinchen VJ; Zahid MN; Flyak AI; Soliman MG; Learn GH; Wang S; Davidson E; Doranz BJ; Ray SC; Cox AL; Crowe JE; Bjorkman PJ; Shaw GM; Bailey JR
    Cell Host Microbe; 2018 Nov; 24(5):717-730.e5. PubMed ID: 30439341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1.
    El-Diwany R; Cohen VJ; Mankowski MC; Wasilewski LN; Brady JK; Snider AE; Osburn WO; Murrell B; Ray SC; Bailey JR
    PLoS Pathog; 2017 Feb; 13(2):e1006235. PubMed ID: 28235087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of HCV resistance to broadly neutralizing antibodies.
    Frumento N; Flyak AI; Bailey JR
    Curr Opin Virol; 2021 Oct; 50():23-29. PubMed ID: 34329953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Junctional and somatic hypermutation-induced CX
    Yi C; Xia J; He L; Ling Z; Wang X; Yan Y; Wang J; Zhao X; Fan W; Sun X; Zhang R; Ye S; Zhang R; Xu Y; Ma L; Zhang Y; Zhou H; Huang Z; Niu J; Long G; Lu J; Zhong J; Sun B
    Cell Mol Immunol; 2021 Mar; 18(3):675-685. PubMed ID: 32235917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.
    Flyak AI; Ruiz S; Colbert MD; Luong T; Crowe JE; Bailey JR; Bjorkman PJ
    Cell Host Microbe; 2018 Nov; 24(5):703-716.e3. PubMed ID: 30439340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency.
    Frumento N; Figueroa A; Wang T; Zahid MN; Wang S; Massaccesi G; Stavrakis G; Crowe JE; Flyak AI; Ji H; Ray SC; Shaw GM; Cox AL; Bailey JR
    J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35588376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
    Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.
    Keck ZY; Pierce BG; Lau P; Lu J; Wang Y; Underwood A; Bull RA; Prentoe J; Velázquez-Moctezuma R; Walker MR; Luciani F; Guest JD; Fauvelle C; Baumert TF; Bukh J; Lloyd AR; Foung SKH
    PLoS Pathog; 2019 May; 15(5):e1007772. PubMed ID: 31100098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
    Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
    J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signatures of V
    Capella-Pujol J; de Gast M; Radić L; Zon I; Chumbe A; Koekkoek S; Olijhoek W; Schinkel J; van Gils MJ; Sanders RW; Sliepen K
    Nat Commun; 2023 Jul; 14(1):4036. PubMed ID: 37419906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.
    Rodrigo C; Walker MR; Leung P; Eltahla AA; Grebely J; Dore GJ; Applegate T; Page K; Dwivedi S; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Luciani F; Lloyd AR; Bull RA;
    Infect Genet Evol; 2017 Apr; 49():88-96. PubMed ID: 28065804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
    Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.